Good tolerance of high dose cytosine arabinoside and methotrexate after severe myelosuppression secondary to intrathecal administration of the same agents

References (7)

1. Butler RW, Hill JM, Steinherz PG, Meyers PA, Finlay JL. Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J Clin Oncol 1994;12:2621-9
2. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12:1667-72
3. Thyss A, Suciu S, Bertrand Y, Mazingue F, Robert A, Vilmer E, Mechinaud F, Benoit Y, Brock P, Ferster A, Lutz P, Boutard P, Marguerite G, Plouvier E, Michel G, Plantaz D, Munzer M, Rialland X, Chantraine JM, Norton L, Solbu G, Philippe N, Otten J. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group. J Clin Oncol 1997;15:1824-30
4. Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, Beuzeboc P, Dorval T, Pouillart P. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 1996;77:1315-23
5. Nagahama T, Maruyama M, Irie T, Yoshida T, Küre N, Ebuchi M. Pharmaco-dynamic study of methotrexate (MTX) during intraperitoneal MTX/5-FU sequential therapy after gastric surgery. Gan To Kagaku Ryoho 1999;26:1786-9
6. Bostrom BC, Erdmann GR, Karnen BA Systemic methotrexate exposure is greater after intrathecal than after oral administration. J Pediatr Hematol Oncol 2003;25:114-7
7. Bleyer WA, Nelson JA, Karnen BA. Accumulation of methotrexate in systemic tissues after intrathecal administration. J Pediatr Hematol Oncol 1997;19:530-2.